The U.S. FDA announced plans to merge multiple adverse event (AE) reporting tools into a single Adverse Event Monitoring System that will ultimately centralize reports across agency centers, including vaccine and drug safety trackers operated with CDC collaboration. The consolidation aims to standardize data collection, speed signal detection and simplify submissions for reporters. Agency materials describe phased migration of legacy systems into the new platform and emphasize interoperability, modernized analytics and improved user interfaces for hospitals, manufacturers and public health partners. The change also raises implementation questions around data mapping, historical continuity and training for regulated stakeholders. For pharma safety teams and pharmacovigilance vendors, the initiative means near‑term resource planning for integration and potential long‑term improvements in signal quality and regulatory interactions.